全球首个专业治疗眼科用药开发的非全身用药氟喹诺酮类药物——Besivance(0.6%贝西沙星悬浮性滴眼剂)近日获得美国FDA批准,用于治疗细菌性结膜炎(俗称红眼病)。
Besivance(TM)是由一种新型局部眼科用抗菌剂制成的无菌滴眼液,对多种病原体有效。2008年12月,FDA咨询委员会投票一致建议批准Besivance。Besivance具有广谱抗菌性,包括引起最为常见的细菌性结膜炎的菌株。细菌性结膜炎是一种全球范围内常见的多发病。
FDA根据8项临床试验的结果批准Besivance。这些临床试验评价了外用抗感染药的疗效、安全性、耐受性、药效学和药代动力学。Besivance疗效评价通过入组了近2400名临床诊断患有细菌性结膜炎的研究对象的随机、双盲临床试验获得。
在临床试验中,实验组康复的时间快于仅含防腐剂的对照组。Besivance对于一岁及以上的儿童也有疗效。临床研究过程中不良反应的发生率不到3%,主要是眼睛发红、视力模糊、眼睛疼痛、刺痒及头痛。Besivance仅为滴眼液,不用于眼部注射。Besivance于2009年第二季度作为处方药在美国上市,市场推广由博士伦和辉瑞公司合作开展。
FDA抗感染及眼科药品办公室主任表示,细菌性结膜炎易感染各年龄层的人群,有效的药物治疗可以减少患者的患病时间并降低感染他人的几率,为医务人员和患者提供多样的治疗手段非常重要。
Manufacturer:
Bausch & Lomb Pharmaceuticals
Pharmacological Class:
Quinolone
Active Ingredient(s):
Besifloxacin 0.6%; oph. susp; contains benzalkonium chloride.
Indication(s):
Susceptible bacterial conjunctivitis.
Pharmacology:
Besifloxacin is a fluoroquinolone with activity against a variety of gram (+) and gram (-) bacteria. Like others in its class, it works by inhibiting bacterial DNA gyrase, which is necessary for replication, transcription, and repair of bacterial DNA, and topoisomerase IV, which is necessary for the partitioning of chromosomal DNA during cell division. It has a different mode of action than that of the aminoglycosides, macrolides, and β-lactam antibiotics, and may therefore provide coverage against pathogens that are resistant to these other antibiotics.
This product is indicated to treat bacterial conjunctivitis caused by susceptible isolates of the following bacteria: CDC coryneform group G, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominus, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, and Streptococcus salivarius.
As with other anti-infectives, prolonged use of besifloxacin may result in overgrowth of non-susceptible organisms, inlcuding fungi. If super-infection occurs, discontinue use and institute alternative therapy. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment and increase the likelihood that bacteria will develop resistance and will not be treatable by besifloxacin or other antibacterial drugs in the future.
Besivance is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
Clinical Trials:
A randomized, double-masked, vehicle-controlled clinical trial was conducted in which patients with bacterial conjunctivitis were dosed with besifloxacin 0.6% ophthalmic suspension three times daily for 5 days. In this trial, besifloxacin was shown to be superior to vehicle in clinical resolution (45% vs. 33%, respectively). Microbiological outcomes showed a statistically significant eradication rate for causative pathogens for besifloxacin compared to vehicle (91% vs. 60%, respectively).
Legal Classification:
Rx
Adults & Children:
<1yr: not recommended. ≥1year: 1 drop in affected eye(s) 3 times daily (4–12 hrs apart) for 7 days. Shake bottle once before use.
Precaution(s):
Remove contact lenses during therapy or if symptomatic. Pregnancy (Cat.C). Nursing mothers.
Adverse Reaction(s):
Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat).
Notes:
Avoid contaminating the applicator tip with material from the eye, fingers, or other source. Wash hands thoroughly prior to use. Invert closed bottle and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).
How Supplied:
Susp—5mL
Last Updated:
7/16/2009